A Two Year Open Label, Randomized, Parallel Group, Blinded Assessment Ophthalmologic Safety Study of Pramipexole IR versus Ropinirole in Early Parkinson's Disease Patients

Kelly L. Sullivan

A Two Year Open Label, Randomized, Parallel Group, Blinded Assessment Ophthalmologic Safety Study of Pramipexole IR versus Ropinirole in Early Parkinson's Disease Patients

Kelly L. Sullivan

Biostatistics, Epidemiology & Environmental Health Sciences

Research output: Other contribution › Other

Original language	American English
State	Published - 2007

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Disciplines

Epidemiology
Public Health

Cite this

@misc{d7f4169b2f10463c9d49d306aa2642ef,

title = "A Two Year Open Label, Randomized, Parallel Group, Blinded Assessment Ophthalmologic Safety Study of Pramipexole IR versus Ropinirole in Early Parkinson's Disease Patients",

author = "Sullivan, \{Kelly L.\}",

note = "Kelly L. Sullivan (Coordinator), {"}A Two Year Open Label, Randomized, Parallel Group, Blinded Assessment Ophthalmologic Safety Study of Pramipexole IR versus Ropinirole in Early Parkinson's Disease Patients,{"} Boehringer Ingelheim, Protocol \# 248.538. (2007-2011).",

year = "2007",

language = "American English",

type = "Other",

}

TY - GEN

T1 - A Two Year Open Label, Randomized, Parallel Group, Blinded Assessment Ophthalmologic Safety Study of Pramipexole IR versus Ropinirole in Early Parkinson's Disease Patients

AU - Sullivan, Kelly L.

N1 - Kelly L. Sullivan (Coordinator), "A Two Year Open Label, Randomized, Parallel Group, Blinded Assessment Ophthalmologic Safety Study of Pramipexole IR versus Ropinirole in Early Parkinson's Disease Patients," Boehringer Ingelheim, Protocol # 248.538. (2007-2011).

PY - 2007

Y1 - 2007

M3 - Other

ER -